Hansoh Pharmaceutical Group Company Limited (3692.HK)
HKD 24.4
(1.24%)
HKD 24.4
(1.24%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 4.19 Billion CNY | 38.58% |
| 2022 | 2.93 Billion CNY | -4.93% |
| 2021 | 3.08 Billion CNY | 3.17% |
| 2020 | 2.98 Billion CNY | 0.85% |
| 2019 | 2.96 Billion CNY | 19.55% |
| 2018 | 2.47 Billion CNY | 19.97% |
| 2017 | 2.06 Billion CNY | 7.14% |
| 2016 | 1.92 Billion CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 2.8 Billion CNY | 0.0% |
| 2023 FY | - CNY | 38.58% |
| 2023 Q2 | 1.21 Billion CNY | 0.0% |
| 2023 Q4 | 1.8 Billion CNY | 0.0% |
| 2022 Q4 | 1.55 Billion CNY | 0.0% |
| 2022 Q2 | 1.37 Billion CNY | 0.0% |
| 2022 FY | - CNY | -4.93% |
| 2021 FY | - CNY | 3.17% |
| 2021 Q2 | 1.46 Billion CNY | 0.0% |
| 2021 Q4 | 1.62 Billion CNY | 0.0% |
| 2020 FY | - CNY | 0.85% |
| 2020 Q4 | 1.54 Billion CNY | 0.0% |
| 2020 Q2 | 1.44 Billion CNY | 0.0% |
| 2019 Q2 | 1.55 Billion CNY | 0.0% |
| 2019 FY | - CNY | 19.55% |
| 2019 Q4 | 1.41 Billion CNY | 0.0% |
| 2018 FY | - CNY | 19.97% |
| 2018 Q4 | 1.08 Billion CNY | 0.0% |
| 2018 Q2 | 1.3 Billion CNY | 0.0% |
| 2017 Q4 | 617.1 Million CNY | 0.0% |
| 2017 Q1 | 517.7 Million CNY | 0.0% |
| 2017 Q2 | 517.7 Million CNY | 0.0% |
| 2017 FY | - CNY | 7.14% |
| 2016 Q4 | 517.7 Million CNY | 0.0% |
| 2016 Q1 | 482.24 Million CNY | 0.0% |
| 2016 FY | - CNY | 0.0% |
| 2016 Q2 | 482.24 Million CNY | 0.0% |
| 2015 Q4 | 482.24 Million CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | -2692.031% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | -41.552% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 3342.136% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | -3590.06% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 8460.141% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | -3723.725% |
| Essex Bio-Technology Limited | 418.37 Million HKD | -903.691% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | -5379.643% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 16146.525% |
| SSY Group Limited | 2.11 Billion HKD | -98.586% |
| JBM (Healthcare) Limited | 204.39 Million HKD | -1954.511% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | -876.741% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 72.787% |